Novogen (NASDAQ:KZIA) Given “Buy” Rating at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Novogen (NASDAQ:KZIA) in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a $34.00 target price on the stock.

A number of other analysts have also commented on the stock. Laidlaw initiated coverage on shares of Novogen in a research note on Wednesday, April 15th. They issued a “buy” rating and a $25.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research note on Tuesday, April 21st. Finally, Lake Street Capital assumed coverage on Novogen in a report on Thursday, June 11th. They set a “buy” rating and a $32.00 price target on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.80.

Novogen Stock Down 0.2%

KZIA stock opened at $13.44 on Wednesday. Novogen has a twelve month low of $4.86 and a twelve month high of $17.40. The business has a 50 day moving average of $13.20 and a 200 day moving average of $9.72.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.